ADC Therapeutics SA Price to Book Ratio 2019-2021 | ADCT

Historical price to book ratio values for ADC Therapeutics SA (ADCT) over the last 10 years. The current price to book ratio for ADC Therapeutics SA as of December 07, 2021 is 7.85.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

ADC Therapeutics SA Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-12-08 21.25 inf
2021-09-30 27.16 0.00
2021-06-30 24.35 0.00
2021-03-31 24.41 0.00
2020-12-31 32.01 0.00
2020-09-30 32.99 $4.90 6.73
2020-06-30 46.81 $2.78 16.86
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.469B $0.002B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71